Intrommune Therapeutics
View On Demand

A Revolutionary Approach To Food Allergy Immunotherapy

About the Event


If you live with food allergies, you live in fear. With every meal, every snack, and every bite comes the opportunity for exposure to an ingredient that can be life-threatening. Peanuts, shellfish, milk, soy, and other foods cause everything from minor irritations like tingling, itching, and rashes, to anaphylactic shock that leads to death. The fear is real for not only over 30 million Americans, but their entire families.

Intrommune Therapeutics is transforming and protecting the lives of more than 220 million people with food allergies by delivering immunotherapeutic agents in specially formulated toothpaste. This new approach for the treatment of food allergies is called oral mucosal immunotherapy (OMIT) and addresses a significant health care need in the industrialized world, where the spread of food allergies has been characterized as an “epidemic.”

Join our webinar to hear from Intrommune Therapeutics CEO, Michael Nelson. He’ll discuss how the company’s technology will transform lives by allowing children and adults with food allergies to no longer live in fear of accidentally eating peanuts, shellfish, soy, gluten or other problem foods, simply by brushing their teeth.

View On-Demand Webinar


SHARE THIS EVENT
Share on facebook
Share on twitter
Share on linkedin

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.